Yizhe Tie

Yizhe Tie

Auto-generated profile, based on publicly available information

Yizhe Tie

The First Affiliated Hospital, Sun Yat-sen University Department of Gastroenterology Guangzhou

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
RCRirong Chen
Rirong Chen
YTYizhe Tie
Yizhe Tie
YHYongle Huang
Yongle Huang
XZXi Zhang
Xi Zhang
ZZZhirong Zeng
Zhirong Zeng
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Background: Clinical remission (CR) is the principal short‐term treatment target in patients with ulcerative colitis (UC). However, whether rapidly achieving CR indicates better outcomes remains unclear.Objectives: We aimed to explore the associations between the timing of CR and therapeutic outcomes in UC.Methods: This study included UC patients from the UNIFI trial. Week‐2 CR and time to CR were the major variables of interest. Endoscopic remission (ER) at week 52 was the primary outcome. Multivariate logistic regression was performed to evaluate the association between variables and outcomes.Results: Week‐2 CR was associated with ER (aOR: 2.37 [95% CI: 1.28, 4.37], p = 0.006) and Histological remission (HR) (aOR: 2.87 [95% CI: 1.42, 5.72], p = 0.003) at week 52. Moreover, C‐reactive protein (CRP) remission could further stratify patients without CR and predict week‐52 outcomes. Patients with clinical activity + CRP remission (aOR: 0.49 [95% CI: 0.26, 0.93], p = 0.039) and clinical activity + CRP activity (aOR: 0.24 [95% CI: 0.11, 0.52], p < 0.001) had gradually decreased likelihood of achieving ER, when compared to those with CR. For time to CR, we found that the earlier to CR, the better endoscopic and histological outcomes patients would attain. Patients achieving CR at weeks 2, 4/8, 12/16 and >16 had gradually reduced proportions of ER (51.9% vs. 40.8% vs. 31.6% vs. 8.8%, p < 0.001) and HR (37.0% vs. 19.8% vs. 17.1% vs. 6.1%, p < 0.001) at week 52. Compared with week 2, achieving CR at weeks 4/8, 12/16 and >16 had 39%, 55% and 92% lower likelihoods of week‐52 ER, respectively.Conclusions: Week‐2 CR indicates better outcomes in UC patients receiving ustekinumab. Moreover, achieving CR more rapidly is associated with higher probability of ER and HR.

23 June 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
RCRirong Chen
Rirong Chen
YTYizhe Tie
Yizhe Tie
XZXi Zhang
Xi Zhang
LLLi Li
Li Li
MCMinhu Chen
Minhu Chen
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Background: Fecal lactoferrin (FL) is associated with disease activity and relapse in ulcerative colitis. However, whether FL could early predict long-term outcomes in ulcerative colitis is poorly understood. Methods: This post-hoc analysis included participants who received biologics and had available data of FL concentration at week 4 from the UNIFI and PURSUIT trials (n = 1063). Therapeutic outcomes, including clinical remission, endoscopic improvement and remission, and histological improvement and remission, were evaluated at the end of maintenance therapy. The incidence of colectomy was observed from week 0 to maximum week 228 in the PURSUIT trial (n = 667). Multivariate logistic and Cox proportional-hazard regression were conducted to evaluate the associations between FL and therapeutic outcomes and colectomy, respectively. Results: A high FL level at week 4 was associated with poor long-term clinical, endoscopic and histologic outcomes. FL >84.5 mu g/mL predicted a low likelihood of clinical (OR [95% CI]: 0.43 [0.32, 0.57]; p < 0.001), endoscopic (OR [95% CI]: 0.40 [0.29, 0.56]; p < 0.001), and histological (OR [95% CI]: 0.27 [0.14, 0.53]; p < 0.001) remission. Moreover, week-4 FL could add prognostic value to fecal calprotectin and clinical and endoscopic scores for informing long-term therapeutic outcomes. For the risk of colectomy, patients with week-4 FL = 20.1 mu g/mL had an incidence rate of 1.10% and 6.39%, respectively. Patients with FL >= 20.1 mu g/mL had a 995% higher risk of colectomy (HR [95% CI], 10.95 [1.45, 82.74]). Conclusion: FL could be a promising prognostic biomarker for long-term therapeutic outcomes and risk of colectomy in patient of ulcerative colitis.

21 October 2025 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
YTYizhe Tie
Yizhe Tie
DWDaiyue Wang
Daiyue Wang
ZFZinan Fan
Zinan Fan
LLLi Li
Li Li
MCMinhu Chen
Minhu Chen
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Background: Magnetic resonance enterography (MRE) is a noninvasive and radiation-free option for managing Crohn’s disease (CD), for which various predictors have been reported to show significant prognostic value. Objectives: The aim of this review was to summarize MRE predictors that indicated poor prognosis, including surgeries, complications, relapses, therapeutic escalations, and persistent pathological changes in patients with CD. Design: Systematic review with meta-analysis. Data sources and methods: Web of Science and PubMed were systematically searched for articles exploring the predictive performance of MRE in patients with luminal CD, with the latest search performed on July 21, 2025. Pooled analyses of odds ratios (OR) and hazard ratios for predicting poor prognosis were conducted using a random-effects model when available. Results: Thirty articles were included in this study. Meta-analysis identified five significant MRE predictors for predicting CD poor prognosis over 12 months, including inflammation (OR 3.40, 95% confidence interval (CI 1.96–5.89)), bowel wall thickening (OR 2.88, 95% CI (1.95–4.25)), strictures (OR 4.95, 95% CI (1.99–12.34)), edema (OR 2.67, 95% CI (1.25–5.69)), and fistula (OR 5.15, 95% CI (2.72–9.76)). Furthermore, scoring systems, such as the Magnetic Resonance Index of Activity (MaRIA) and Clermont scores, showed significant predictive values. Conclusion: MRE is effective in predicting the prognosis of patients with CD, with significant predictors including inflammation, bowel wall thickening, strictures, edema, fistula, and MaRIA score. Trial registration: The study protocol was registered in the International Prospective Register of Systematic Reviews (registration number: CRD42022365965).

3 July 2026 in Crohn's & Colitis 360
Verified
Journal Article
Open access
YTYizhe Tie
Yizhe Tie
FSFengyuan Su
Fengyuan Su
JZJianwu Zhang
Jianwu Zhang
MZMinhui Zheng
Minhui Zheng
NLNingyi Li
Ningyi Li
Shenghong ZhangShenghong Zhang
Shenghong Zhang
Background: Longitudinal trajectories and the optimal timing for evaluating clinical activity remains unclear in ulcerative colitis (UC) patients receiving biologics. Methods: This study included 2,705 UC patients from five trials and collected 28,807 records of partial Mayo scores (PMS) from baseline to week 52. Latent class growth mixed model was performed to construct one-year PMS trajectories. Logistic regression assessed the association between PMS trajectories and one-year therapeutic outcomes, and endoscopic remission was the primary outcome. Spearman correlation was utilized to identify the timepoints of PMS most correlated with the trajectories. Results: Five trajectories of clinical activity were identified, including rapid remission (n = 590, 21.8%), delayed remission (n = 316, 11.7%), mild improvement (n = 748, 27.7%), slow improvement (n = 915, 33.8%), and relapse-fluctuation (n = 136, 5.0%) groups. Endoscopic and histological remission rates exhibited a progressive decline across trajectory groups, with the highest probability in the rapid remission group and sequentially lower probabilities in the delayed remission, mild/slow improvement, and relapse-fluctuation groups (p < 0.001). Week-20 PMS demonstrated the strongest correlation with clinical activity trajectories (correlation coefficient = 0.7867, p < 0.001), with an area under curve of 0.9311 (95%CI: 0.9183,0.9440). Furthermore, Week-20 PMS could independently predicted one-year endoscopic (aOR[95%CI] 0.59[0.54, 0.65], p < 0.001) and histological (aOR[95%CI] 0.61[0.53-0.70], p < 0.001) remission. Conclusions: UC patients receiving biologics would exhibit five distinct trajectories of clinical activity. Week 20 is a potential intermediate timepoint for clinical activity assessment to inform long-term outcomes.